Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Capital One (COF) downgraded to Underperform from Neutral at Wedbush with analyst Henry Coffey saying ROE from operations is much lower than expected, and return on capital measures are sub-optimal. 2. Weyerhaeuser (WY) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos saying his thesis has played out and catalysts are limited in the intermediate term. 3. Buffalo Wild Wings (BWLD) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh saying the proxy fight and management shake-up has created uncertainty regarding the company's future and said a downward revision to guidance is likely due to continued margin pressures, soft topline trends, and lack of near-term catalysts. 4. GlaxoSmithKline (GSK) downgraded to Neutral from Buy at Citi with analyst Andrew Baum saying he believes the market is under-appreciating the slowing of the company's HIV market growth. 5. Oneok (OKE) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Tom Abrams saying risk/reward is balanced. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Reports Q1 revenue $9.4B, consensus $9.34B.

Due to a rapidly changing epidemiological environment following the end of the COVID-19 pandemic, CureVac and GSK decided to end the Pandemic Preparedness Agreement jointly concluded with the Federal Republic of Germany in April 2022. This decision was made after consultation with the German Federal Ministry of Health and the German Center for Pandemic Vaccines and Therapeutics. The agreement included the provision of production capacity and supply of mRNA-based vaccines in the event of a public health emergency in Germany. Termination will take effect on May 31, 2024, with no further financial obligations. Completion of CureVac's GMP IV manufacturing plant for the production mRNA-based vaccines is unaffected and progressing. Contingent upon regulatory approval, the facility is expected to be certified in the second half of 2024.

CureVac (CVAC) announced the start of the Phase 1 part of a combined Phase 1/2 study of an investigational influenza A pre-pandemic vaccine candidate developed in collaboration with GSK (GSK). The H5N1 avian influenza virus is considered a potential future pandemic threat, known to sporadically cross species from its original bird host to other animal hosts and humans. The monovalent vaccine candidate is based on CureVac's proprietary second-generation mRNA backbone and encodes an influenza A H5-antigen. The combined Phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of an investigational influenza A pre-pandemic vaccine candidate in healthy younger adults aged 18 to 64 and healthy older adults aged 65 to 85. In the initial Phase 1 dose-escalation part of the study, up to five dose levels will be assessed compared to a placebo control. The study will be conducted in the United States. The broad CureVac-GSK infectious disease collaboration was first announced in July 2020. It focuses on applying CureVac's mRNA-technology to the development of new products for infectious disease targets.